Regulus Therapeutics Inc. (NASDAQ:RGLS) traded up 5.6% on Monday . The stock traded as high as $1.52 and last traded at $1.32. 2,878,636 shares were traded during mid-day trading, an increase of 243% from the average session volume of 838,206 shares. The stock had previously closed at $1.25.

Several brokerages have recently weighed in on RGLS. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Wedbush restated an “ourperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research note on Monday, August 7th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. Chardan Capital lowered Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets set a $1.00 target price on Regulus Therapeutics and gave the company a “hold” rating in a research report on Monday, June 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $3.63.

The firm’s market cap is $137.00 million. The firm has a 50-day moving average of $1.10 and a 200-day moving average of $1.24.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. Analysts forecast that Regulus Therapeutics Inc. will post ($1.02) EPS for the current year.

In other Regulus Therapeutics news, insider Joseph P. Hagan purchased 219,780 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was bought at an average cost of $0.91 per share, with a total value of $199,999.80. Following the transaction, the insider now directly owns 241,297 shares in the company, valued at approximately $219,580.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William H. Rastetter purchased 274,725 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, with a total value of $249,999.75. The disclosure for this purchase can be found here. Insiders bought a total of 549,450 shares of company stock worth $500,000 over the last ninety days. Insiders own 4.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 93,295 shares during the period. Wedbush Securities Inc. increased its stake in shares of Regulus Therapeutics by 10.3% during the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 18,600 shares in the last quarter. South Dakota Investment Council lifted its holdings in shares of Regulus Therapeutics by 16.3% during the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after purchasing an additional 186,130 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Regulus Therapeutics by 15.7% during the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 9,804 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in shares of Regulus Therapeutics by 131.5% during the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 61,373 shares during the last quarter. Institutional investors and hedge funds own 21.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Regulus Therapeutics Inc. (RGLS) Trading 5.6% Higher” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/regulus-therapeutics-inc-rgls-trading-5-6-higher/1603962.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.